Education
About Us
Working with TipRanks
Follow Us
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Total Valuation
Kiora Pharmaceuticals has a market cap or net worth of $9.17M. The enterprise value is -$8.53M.
Market Cap$9.17M
Enterprise Value-$8.53M
Share Statistics
Kiora Pharmaceuticals has 3,433,491 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,433,491
Owned by Insiders3.19%
Owned by Institutions26.06%
Financial Efficiency
Kiora Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 9.39%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)9.39%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee1.33M
Profits Per Employee299.56K
Employee Count12
Asset Turnover0.44
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kiora Pharmaceuticals is 4.7. Kiora Pharmaceuticals’s PEG ratio is ―.
PE Ratio4.7
PS Ratio―
PB Ratio―
Price to Fair Value0.50
Price to FCF―
Price to Operating Cash Flow-1.27
PEG Ratio―
Income Statement
In the last 12 months, Kiora Pharmaceuticals had revenue of 16.02M and earned 3.59M in profits. Earnings per share was 0.93.
Revenue16.02M
Gross Profit16.00M
Operating Income4.51M
Pretax Income5.66M
Net Income3.59M
EBITDA5.75M
Earnings Per Share (EPS)0.93
Cash Flow
In the last 12 months, operating cash flow was -7.84M and capital expenditures 12.84K, giving a free cash flow of -7.83M billion.
Operating Cash Flow-7.84M
Free Cash Flow-7.83M
Free Cash Flow per Share-2.28
Dividends & Yields
Kiora Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-25.41%
50-Day Moving Average2.85
200-Day Moving Average3.20
Relative Strength Index (RSI)50.64
Average Volume (3m)85.95K
Important Dates
Kiora Pharmaceuticals upcoming earnings date is Nov 17, 2025, TBA (Confirmed).
Last Earnings DateAug 8, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date―
Financial Position
Kiora Pharmaceuticals as a current ratio of 4.94, with Debt / Equity ratio of 1.95%
Current Ratio4.94
Quick Ratio4.94
Debt to Market Cap<0.01
Net Debt to EBITDA-0.65
Interest Coverage Ratio210.31
Taxes
In the past 12 months, Kiora Pharmaceuticals has paid 2.07M in taxes.
Income Tax2.07M
Effective Tax Rate0.36
Enterprise Valuation
Kiora Pharmaceuticals EV to EBITDA ratio is 1.57, with an EV/FCF ratio of 1.06.
EV to Sales0.56
EV to EBITDA1.57
EV to Free Cash Flow1.06
EV to Operating Cash Flow1.06
Balance Sheet
Kiora Pharmaceuticals has $20.67M in cash and marketable securities with $430.41K in debt, giving a net cash position of -$20.24M billion.
Cash & Marketable Securities$20.67M
Total Debt$430.41K
Net Cash-$20.24M
Net Cash Per Share-$5.89
Tangible Book Value Per Share$4.92
Margins
Gross margin is 0.00%, with operating margin of 28.15%, and net profit margin of 22.44%.
Gross Margin0.00%
Operating Margin28.15%
Pretax Margin35.33%
Net Profit Margin22.44%
EBITDA Margin35.87%
EBIT Margin35.46%
Analyst Forecast
The average price target for Kiora Pharmaceuticals is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside302.93% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-100.00%
EPS Growth Forecast49.47%